Dr. Laura Coates discusses "what is fatigue" based on clinical outcome and disease activity measures in PsA. Three main groups stood out in predicting fatigue in these patients: level of inflammation, chronic pain, and chronicity of PsA disease. #EULAR2021 @RheumNow https://t.co/pFYRb1X7pT

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.

Check out our Lupus coverage from #EULAR2021 https://t.co/Gmh4sFv4Jl https://t.co/OihiiomZBd

• https://bit.ly/3z1NV2T

#EULAR2021 How to Measure Success in Lupus? Dr. Kathryn Dao ( @KDAO2011 ) https://t.co/z8c8moIQCa https://t.co/0BLeFJyZD4

• https://bit.ly/3vO6Ig9

What's your EULAR IQ? Test your knowledge! #EULAR2021 https://t.co/psumBpzUc7 https://t.co/w5Vg68RVLs

• https://bit.ly/3z0nI56

Fecal Transplantation as Potential PsA Treatment: Dr. Eric Dein ( @ejdein1) #EULAR2021 https://t.co/ItYAEIJZSW https://t.co/uHnY9cWLEj

• https://bit.ly/3vO1Rfb

JAKi to #JAKi cycling is common in #rheumatoidarthritis Rx. Opal registry >53000 pts, 1/4 treated with JAKi (4000) & 44% new starts were Jaki. JAKi to JAKi cycling was >40%! POS0223 #EULAR2021 ⁦@RheumNow⁩ https://t.co/XV7wVJsE9c

"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow https://t.co/nIDksfTe7h

Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021 https://t.co/S0ownscRKv https://t.co/PJODe0U6wr

• https://bit.ly/34KzliI

How Do You Measure Success When It Comes to SLE? by Dr. Kathryn Dao ( @KDAO2011 ) #EULAR2021 https://t.co/aVKY4B9CfW https://t.co/ffruCDouaE

• https://bit.ly/2RZnfzv

#EULAR2021 Complex Immune Disturbances in ANA+ Individuals: Drs. Yusof and Hassan https://t.co/nvSU7ArEUU https://t.co/7pJ5ypqDJn

• https://bit.ly/3z1mp5B

Dr Hellgren on pregnancy outcomes in RA 📈disease activity assoc preterm birth and small gestational age. Low disease activity = no increased risk compared controls @RheumNow #EULAR2021 Abstr#OP0210 https://t.co/L26xWhIFv6